FDA Approves Crizotinib for Pediatric ALK+ ALCL Indication

Crizotinib—a tyrosine kinase inhibitor with activity against ALK, ROS1, and MET—was granted FDA approval for use in pediatric patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

Study shows that genomic tumor profiling of pediatric tumors can enhance clinical care

Pushing T cells down "memory lane" may improve cancer therapy

Previous Cancer Not Seen to Raise Thyroid Surgery Risks for Children

Bortezomib extends survival of children with newly diagnosed T-cell lymphoblastic lymphoma

A drug and a DNA variant increase heart disease risk in cancer survivors

Researchers Identify RAD21 Variants in Pediatric Lymphoblastic Leukemia or Lymphoma

Adult survivors of childhood cancer often undertreated for cardiovascular risk factors

Dabrafenib + Trametinib Improve Overall Response Rates in Pediatric Patients with Low-Grade Gliomas

Study confirms the benefits of 'bridge therapy' for some children with high-risk neuroblastoma

Study identifies best treatment for rare childhood cancer

Recent Posts